Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 14, Issue 6, 2015, Pages 720-726

  Chmiel, James F ^a,b   Konstan, Michael W ^a,b   Accurso, Frank J ^c   Lymp, James ^d   Mayer Hamblett, Nicole ^e   VanDevanter, Donald R ^b   Rose, Lynn M ^e   Ramsey, Bonnie W ^e  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL COLORADO   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Anti inflammatory drugs; Biomarkers; Cystic fibrosis; Ibuprofen; Induced sputum; Inflammation

Indexed keywords

IBUPROFEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOCYTE COUNT; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; CHEMISTRY; CLINICAL TRIAL; IMMUNOLOGY; INFLAMMATION; SPUTUM; YOUNG ADULT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; FEMALE; HUMANS; IBUPROFEN; INFLAMMATION; INTERLEUKIN-6; MALE; SPUTUM; YOUNG ADULT;

EID: 84946490378     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.03.007     Document Type: Article

References (43)

1. Davis P.B., Drumm M., Konstan M.W. Cystic fibrosis: state of the art. Am J Respir Crit Care Med 1996, 154:1229-1256.
2. Chmiel J.F., Berger M., Konstan M.W. The role of inflammation in the pathophysiology of cystic fibrosis lung disease. Clin Rev Allergy Immunol 2002, 23:5-27.
3. Nichols D., Chmiel J., Berger M. Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. Clin Rev Allergy Immunol 2008, 34:146-162.
4. CysticFibrosis Foundation Patient Registry 2009 Annual Report 2010, Cystic Fibrosis Foundation, Bethesda, MD.
5. Konstan M.W., Hilliard K.A., Norvell T.M., Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994, 150:448-454.
6. Khan T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., Riches D.W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
7. Konstan M.W., Davis P.B. Pharmacological approach for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev 2002, 54:1409-1423.
8. Chmiel J.F., Konstan M.W. Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med 2005, 4:255-273.
9. Chmiel J.F., Konstan M.W. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007, 28:331-346.
10. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B., Cystic Fibrosis Foundation Pulmonary Therapeutics Committee, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176:957-969.
11. Mogayzel P.J., Naureckas E.T., Robinson K.A., Mueller G., Hadjiliadis D., Hoag J.B., Pulmonary Clinical Practice Guidelines Committee, et al. Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013, 187:680-689.
12. Lands L.C., Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 2007, 4:CD001505.
13. Konstan M.W., Vargo K.M., Davis P.B. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection: implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis 1990, 141:186-192.
14. Konstan M.W., Krenicky J.E., Finney M.R., Kirchner H.L., Hilliard K.A., Hilliard J.B., et al. Effect of ibuprofen on neutrophils migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther 2003, 306:1086-1091.
15. Konstan M.W., Byard P.J., Hoppel C.L., Davis P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332:848-854.
16. Lands L.C., Milner R., Cantin A.M., Manson D., Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007, 151:249-254.
17. 1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007, 176:1084-1089.
18. Oermann C.M., Sockrider M.M., Konstan M.W. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest 1999, 115:1053-1058.
19. Konstan M.W. Ibuprofen therapy for cystic fibrosis lung disease: revisited. Curr Opin Pulm Med 2008, 14:567-573.
20. Eigen H., Rosenstein B.J., FitzSimmons S., Schidlow D.V., Cystic Fibrosis Foundation Prednisone Trial Group A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995, 126:515-523.
21. Konstan M.W., Wagener J.S., Yegin A., Millar S.J., Pasta D.J., VanDevanter D.R. Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint. J Cyst Fibros 2010, 9:332-338.
22. Balfour-Lynn I.M., Klein N.J., Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997, 77:124-130.
23. Dauletbaev N., Viel K., Behr J., et al. Effects of short-term inhaled fluticasone on oxidative burst of sputum cells in cystic fibrosis patients. Eur Respir J 1999, 14:1150-1155.
24. Equi A., Balfour-Lynn I.M., Bush A., Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984.
25. Gibson R.L., Emerson J., Mayer-Hamblett N., Burns J.L., McNamara S., Accurso F.J., et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007, 42:610-623.
26. Gibson R.L., Emerson J., McNamara S., Burns J.L., Rosenfeld M., Yunker A., Cystic Fibrosis Therapeutics Development Network Study Group, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003, 167:841-849.
27. Karpati F., Hjelte F.L., Wretlind B. TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment. Scand J Infect Dis 2000, 32:75-79.
28. Moss R.B., Mayer-Hamblett N., Wagener J., Daines C., Hale K., Ahrens R., et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 2005, 39:209-218.
29. Moss R.B., Mistry S.J., Konstan M.W., Pilewski J.M., Kerem E., Tal-Singer R., CF2110399 Investigators, et al. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros 2012, 12:241-248.
30. Ordoñez C.L., Henig N.R., Mayer-Hamblett N., Accurso F.J., Burns J.L., Chmiel J.F., et al. Inflammatory and microbiologic markers in induced sputum following IV antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:1471-1475.
31. Paul K., Rietschel E., Ballmann M., Griese M., Worlitzsch D., Shute J., Bronchoalveolar Lavage for the Evaluation of Antiinflammatory Treatment Study Group, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004, 169:719-725.
32. Schiøtz P.O., Jørgensen M., Flensborg E.W., Faerø O., Husby S., Høiby N., et al. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: a longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Acta Paediatr Scand 1983, 72:283-287.
33. Wojtczak H.A., Kerby G.S., Wagener J.S., Copenhaver S.C., Gotlin R.W., Riches D.W., et al. Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2001, 32:293-302.
34. Mayer-Hamblett N., Aitken M.L., Accurso F.J., Kronmal R.A., Konstan M.W., Burns J.L., et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007, 175:822-828.
35. VanDevanter D.R., Rasouliyan L., Murphy T.M., Morgan W.J., Ren C.L., Konstan M.W., Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, et al. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol 2008, 43:739-744.
36. Henig N.R., Tonelli M.R., Pier M.V., Burns J.L., Aitken M.L. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 2001, 56:306-311.
37. McGarvey L.P., Dunbar K., Martin S.L., Brown V., Macmahon J., Ennis M., et al. Cytokine concentrations and neutrophil elastase activity in bronchoalveolar lavage and induced sputum from patients with cystic fibrosis, mild asthma and healthy volunteers. J Cyst Fibros 2002, 1:269-275.
38. Sagel S.D., Chmiel J.F., Konstan M.W. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 2007, 4:406-417.
39. Knudson R.J., Lebowitz M.D., Holberg C.J., Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983, 127:725-734.
40. Minkler P.E., Hoppel C.L. Determination of ibuprofen in human plasma by high-performance liquid chromatography. J Chromatogr 1988, 428:388-394.
41. Hilliard J.B., Konstan M.W., Davis P.B. Inflammatory mediators in CF patients. Methods Mol Med 2002, 70:409-431.
42. Gutierrez J.P., Grimwood K., Armstrong D.S., Carlin J.B., Carzino R., Olinsky A., et al. Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. Eur Respir J 2001, 17:281-286.
43. Meyer K.C., Sharma A. Regional variability of lung inflammation in cystic fibrosis. Am J Respir Crit Care Med 1997, 156:1536-1540.